然而，三星Bioepis近日与一家未透露名称的“垂直整合健康集团”达成合作，提前以自有品牌销售其仿制药Pyzchiva，并于本周一正式上市。强生指控此举“明显违反协议”，构成“秘密且故意的违约行为”，可能对Stelara的市场份额造成“不可逆的损害”。

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

克罗恩病，这个听起来似乎遥不可及的名字，却是许多人生活中的真实困扰。你是否听说过这种疾病，它不仅影响生活质量，还可能导致严重的身体不适？近年来，医药行业的发展给患者带来了希望，尤其是荃信生物-B（02509）近日获得的乌司奴单抗（Stelara®）对于克罗恩病的上市许可申请，无疑为患者的抗争铺就了一条新道路。 克罗恩病是一种慢性肠道炎症性疾病，患者通常经历腹痛、腹泻等令人难以忍受的症状。根据最新的 ...

Pharmacy- and manufacturer-neutral approach offers members access to therapeutically equivalent, lower cost alternativesSAN DIEGO--(BUSINESS WIRE)--MedImpact Healthcare Systems, the nation’s largest ...

2月12日，华东医药发布关于全资子公司收到药品注册受理通知书的公告。披露子公司杭州中美华东制药有限公司收到国家药品监督管理局（NMPA）签发的《受理通知书》，由中美华东申报的乌司奴单抗注射液（静脉输注）和乌司奴单抗注射液（研发代码：HDM3001-2/QX001S）用于克罗恩病的上市许可申请和补充申请获得受理。HDM3001（Q ...

Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...